Description of HIV-1 Group M Molecular Epidemiology and Drug Resistance Prevalence in Equatorial Guinea from Migrants in Spain

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Yebra, Gonzalo ^a   de Mulder, Miguel ^a   Holguín, África ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; POL PROTEIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; EQUATORIAL GUINEA; FEMALE; GENE CLUSTER; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMIGRANT; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; PHYLOGENY; SPAIN; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; CLUSTER ANALYSIS; DRUG RESISTANCE, VIRAL; EQUATORIAL GUINEA; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LIKELIHOOD FUNCTIONS; MALE; MOLECULAR EPIDEMIOLOGY; PREVALENCE; SPAIN; TRANSIENTS AND MIGRANTS;

EID: 84878035421     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064293     Document Type: Article

References (30)

1. Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, et al. (2006) Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 313: 523-526.
2. Vidal N, Peeters M, Mulanga-Kabeya C, Nzilambi N, Robertson D, et al. (2000) Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa. J Virol 74: 10498-10507.
3. UNAIDS (2012) Equatorial Guinea National Progress Report. Available: http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries/ce_GQ_Narrative_Report.pdf. Accessed 28 January 2013.
4. Ortiz M, Sanchez I, Gonzalez MP, Leon MI, Abeso N, et al. (2001) Molecular epidemiology of HIV type 1 subtypes in Equatorial Guinea. AIDS Res Hum Retroviruses 17: 851-855.
5. Djoko CF, Wolfe ND, Vidal N, Tamoufe U, Montavon C, et al. (2010) HIV type 1 pol gene diversity and genotypic antiretroviral drug resistance mutations in Malabo, Equatorial Guinea. AIDS Res Hum Retroviruses 26: 1027-1031.
6. Hemelaar J, Gouws E, Ghys PD, Osmanov S, (2011) Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 25: 679-689.
7. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, et al. (2011) HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 11: 750-759.
8. Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, et al. (2012) Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 380: 1250-1258.
9. Aghokeng AF, Kouanfack C, Laurent C, Ebong E, Atem-Tambe A, et al. (2011) Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients. AIDS 25: 2183-2188.
10. Aghokeng AF, Vergne L, Mpoudi-Ngole E, Mbangue M, Deoudje N, et al. (2009) Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries. Antivir Ther 14: 401-411.
11. Ceccarelli L, Salpini R, Moudourou S, Cento V, Santoro MM, et al. (2012) Characterization of drug resistance mutations in naive and ART-treated patients infected with HIV-1 in Yaounde, Cameroon. J Med Virol 84: 721-727.
12. Mintsa-Ndong A, Caron M, Plantier JC, Makuwa M, Le Hello S, et al. (2009) High HIV Type 1 prevalence and wide genetic diversity with dominance of recombinant strains but low level of antiretroviral drug-resistance mutations in untreated patients in northeast Gabon, Central Africa. AIDS Res Hum Retroviruses 25: 411-418.
13. Toro C, Jiménez V, Rodríguez C, Del Romero J, Rodés B, et al. (2006) Molecular and epidemiological characteristics of blood-borne virus infections among recent immigrants in Spain. J Med Virol 78: 1599-1608.
14. Yebra G, de Mulder M, Pérez-Elías MJ, Pérez-Molina JA, Galán JC, et al. (2011) Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population. PLOS ONE 6: e26757.
15. de Mulder M, Yebra G, Martín L, Prieto L, Mellado MJ, et al. (2011) Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain. J Antimicrob Chemother 66: 2362-2371.
16. Holguín Á, de Mulder M, Yebra G, López M, Soriano V, (2008) Increase of non-B subtypes and recombinants among newly diagnosed HIV-1 native Spaniards and immigrants in Spain. Curr HIV Res 6: 327-334.
17. Yebra G, Holguín Á, Pillay D, Hué S, (2013) Phylogenetic and demographic characterization of HIV-1 transmission in Madrid, Spain. Infect Genet Evol 14: 232-239.
18. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. (2009) Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLOS ONE 4: e4724.
19. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, et al. (2011) 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 19: 156-164.
20. UNAIDS (2011) 2010 Report on the global AIDS epidemic Available: http://www.unaids.org/documents/20101123_GlobalReport_em.pdf.Accessed 28 January 2013.
21. Holguín Á, Álvarez A, Soriano V, (2002) High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid. AIDS 16: 1163-1170.
22. Holguín Á, Álvarez A, Soriano V, (2005) Differences in the length of gag proteins among different HIV type 1 subtypes. AIDS Res Hum Retroviruses 21: 886-893.
23. Yebra G, de Mulder M, Martín L, Rodríguez C, Labarga P, et al. (2012) Most HIV type 1 non-B infections in the Spanish cohort of antiretroviral treatment-naive HIV-infected patients (CoRIS) are due to recombinant viruses. J Clin Microbiol 50: 407-413.
24. Faria NR, Suchard MA, Abecasis A, Sousa JD, Ndembi N, et al. (2012) Phylodynamics of the HIV-1 CRF02_AG clade in Cameroon. Infect Genet Evol 12: 453-460.
25. Véras NM, Santoro MM, Gray RR, Tatem AJ, Lo Presti A, et al. (2011) Molecular epidemiology of HIV type 1 CRF02_AG in Cameroon and African patients living in Italy. AIDS Res Hum Retroviruses 27: 1173-1182.
26. WHO (2012) World Health Organization HIV drug resistance report. Available: http://www.who.int/hiv/pub/drugresistance/report2012/en/index.html. Accessed 28 January 2013.
27. Ndembi N, Hamers RL, Sigaloff KC, Lyagoba F, Magambo B, et al. (2011) Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala. AIDS 25: 905-910.
28. Hamers RL, Sigaloff KC, Wensing AM, Wallis CL, Kityo C, et al. (2012) Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis 54: 1660-1669.
29. Pérez-Molina JA, Rillo MM, Suárez-Lozano I, Casado Osorio JL, Cobo RT, et al. (2010) Do HIV-infected immigrants initiating HAART have poorer treatment-related outcomes than autochthonous patients in Spain? Results of the GESIDA 5808 study. Curr HIV Res 8: 521-530.
30. Billong SC, Fokam J, Nkwescheu AS, Kembou E, Milenge P, et al. (2012) Early warning indicators for HIV drug resistance in Cameroon during the year 2010. PLOS ONE 7: e36777.